Breast Cancer Research and Treatment **29**: 309, 1994.

Author index, Volume 29

Alexieva-Figusch J 73
Alvarado ME 169
Andrieu C 85

Baselga J 127
Bebók Z 229
Bélanger A 203
Bevilacqua P 59
Birkenhäger JC 161
Blamey RW 117,259
Bolanča A 279
Bolla M 265
Boracchi P 59
Brandt R 11
Buurman CJ 161

Calaf G 169
Cannon P 117
Cantwell B 271
Carstensen J 179
Chambaz EM 265
Chedin M 265
Christensen IJ 297
Chrysogelos SA 29
Ciardiello R 11
Clarke R 141
Colonna M 265
Cox T 169

Dickson RB 29
Díez-Itza I 247

Ebeling K 287
Ellis IO 117,259
Elston CW 259
Estrada S 169

Floiras JL 85
Foekens JA 73
Fox SB 41,109

Gasparini G 59,97
Gee JMW 117
Greenall M 41,109
Grosse R 287
Gullick WJ 3
Gumbrell L 271

Hacène K 85
Hajba A 223
Halliwell B 307
Harris AL 1,41,109
Hastrich D 41
Hilakivi-Clarke L 141
Holck S 297
Hollyer J 41,109

Klijn JGM 73
Končar M 279
Kordić D 279
Kusić Z 279

Labrie F 203
Larsen JK 297
Leek RD 109
Lennard T 271
Li S 203
Lind M 271
Lippman ME 141
Lönn S 237
Lönn U 237
Look MP 73
López-Boado YS 247
López-Otín C 247

Lukač J 279
Lykkesfeldt A 297

Magdelénat H 85
Manning DL 117
Márkus B 229
Marron-Charrière J 265
Martin PM 85
McClelland RA 117
Mendelsohn J 127
Messetti M 59
Millward M 271
Minguillon C 287
Möhner M 287

Németh P 229
Nicholson RI 117,259
Nilsson B 237
Nordenskjöld B 179
Normanno N 11

Osaki A 51

Panh MH 265
Pasquier D 265
Pearson D 259
Pedersen L 297
Pols HAP 161
Portengen H 73
Pozza F 59
Pyrhönen S 223

Rajkumar T 3
Rice-Evans C 307
Robertson JFR 117,259
Robinson A 271
Romain S 85

Rostaing-Puissant B 265
Rowland J 141
Russo J 169

Salomon DS 11
Schiødt T 297
Schönborn I 287
Smith K 41,109
Spitzer E 287
Spyratos F 85
Stål O 179
Stenkvist B 237
Sun X-F 179

Tahin Q 169
Thomas T 189
Thomas TJ 189
Toge T 51
Toi M 51
Tolivia J 247
Tominaga T 51

Valavaara R 223
van Leeuwen JPTM 161
van Putten WLJ 73
Vink-van Wijngaarden T 161
Vuorinen J 223

Weidner N 59,97
Winckel P 265
Wingren S 179
Wiseman H 307

Yan X 203

Zschiesche W 287

Breast Cancer Research and Treatment **29**: 309, 1994.

Author index, Volume 29

Alexieva-Figusch J 73
Alvarado ME 169
Andrieu C 85

Baselga J 127
Bebók Z 229
Bélanger A 203
Bevilacqua P 59
Birkenhäger JC 161
Blamey RW 117,259
Bolanča A 279
Bolla M 265
Boracchi P 59
Brandt R 11
Buurman CJ 161

Calaf G 169
Cannon P 117
Cantwell B 271
Carstensen J 179
Chambaz EM 265
Chedin M 265
Christensen IJ 297
Chrysogelos SA 29
Ciardiello R 11
Clarke R 141
Colonna M 265
Cox T 169

Dickson RB 29
Díez-Itza I 247

Ebeling K 287
Ellis IO 117,259
Elston CW 259
Estrada S 169

Floiras JL 85
Foekens JA 73
Fox SB 41,109

Gasparini G 59,97
Gee JMW 117
Greenall M 41,109
Grosse R 287
Gullick WJ 3
Gumbrell L 271

Hacène K 85
Hajba A 223
Halliwell B 307
Harris AL 1,41,109
Hastrich D 41
Hilakivi-Clarke L 141
Holck S 297
Hollyer J 41,109

Klijn JGM 73
Končar M 279
Kordić D 279
Kusić Z 279

Labrie F 203
Larsen JK 297
Leek RD 109
Lennard T 271
Li S 203
Lind M 271
Lippman ME 141
Lönn S 237
Lönn U 237
Look MP 73
López-Boado YS 247
López-Otín C 247

Lukač J 279
Lykkesfeldt A 297

Magdelénat H 85
Manning DL 117
Márkus B 229
Marron-Charrière J 265
Martin PM 85
McClelland RA 117
Mendelsohn J 127
Messetti M 59
Millward M 271
Minguillon C 287
Möhner M 287

Németh P 229
Nicholson RI 117,259
Nilsson B 237
Nordenskjöld B 179
Normanno N 11

Osaki A 51

Panh MH 265
Pasquier D 265
Pearson D 259
Pedersen L 297
Pols HAP 161
Portengen H 73
Pozza F 59
Pyrhönen S 223

Rajkumar T 3
Rice-Evans C 307
Robertson JFR 117,259
Robinson A 271
Romain S 85

Rostaing-Puissant B 265
Rowland J 141
Russo J 169

Salomon DS 11
Schiødt T 297
Schönborn I 287
Smith K 41,109
Spitzer E 287
Spyratos F 85
Stål O 179
Stenkvist B 237
Sun X-F 179

Tahin Q 169
Thomas T 189
Thomas TJ 189
Toge T 51
Toi M 51
Tolivia J 247
Tominaga T 51

Valavaara R 223
van Leeuwen JPTM 161
van Putten WLJ 73
Vink-van Wijngaarden T 161
Vuorinen J 223

Weidner N 59,97
Winckel P 265
Wingren S 179
Wiseman H 307

Yan X 203

Zschiesche W 287

Breast Cancer Research and Treatment **29**: 311-314, 1994.

Subject index, Volume 29

alcohol consumption
  interaction with psychosocial factors in breast cancer 141-160
amphiregulin
  EGF-related ligands in autocrine/juxtacrine growth 11-27
amplification
  of EGFR and related (erbB) genes 3-9
angiogenesis
  with EGF receptor in prognosis 97-107, 109-116
animal models
  psychosocial factors, stress, and breast cancer development 141-160
antiestrogens
  high-dose toremifene after tamoxifen failure 223-228
antioxidants
  possible function of tamoxifen 307-308
autocrine growth factors
  EGF-related peptides 11-27

benzo(a)pyrene
  transformation of MCF-10 cells 169-177
breast cyst fluid
  induction of Zn-α_2-glycoprotein by glucocorticoids, androgens 247-258

c-erbB receptor family
  expression and overexpression in breast cancer 3-9
c-erbB-2
  see also erbB-2
c-erbB-2 ligands
  in autocrine/juxtacrine growth 11-27
cathepsin D
  no change on transformation of MCF-10 cells 169-177
chemotherapy
  enhancement by addition of anti-EGFR antibodies 127-138
  ifosfamide/doxorubicin combination 271-277
cripto-1
  EGF-related ligands in autocrine/juxtacrine growth 11-27
cytokeratins
  S-phase by flow cytometry on cytokeratin-positive cells 179-187

dehydroepiandrosterone (DHEA)
  DMBA tumor prevention in rats 203-217
dietary fat
  interaction with psychosocial factors in breast cancer 141-160
DMBA (7,12-dimethylbenz[a]anthracene)
  transformation of MCF-10 cells 169-177
DMBA rat mammary tumors
  prevention by circulating dehydroepiandrosterone 203-217
doxorubicin
  combination with ifosfamide 271-277

EGF
  and related ligands in autocrine/juxtacrine growth 11-27
EGF receptor
  as a therapeutic target using monoclonal antibodies 127-138
  association with proliferation (Ki67) 51-58
  association with emerging transformation of MCF-10 cells 169-177
  immunocytochemical association with Ki67, p53 59-71
  immunocytochemistry vs. binding assays 51-58
  immunoenzymatic assay on solubilized fraction, in prognosis 85-95
  in prognosis 41-49, 51-58, 59-71, 73-83
  no prognostic value in 229 patients 265-270
  oncogene interactions 29-40
  regulation 29-40
  role in breast cancer, introduction 1-2
  special issue 1-138
  type I growth factor receptor family 3-9

EGF receptor (cont.)
with angiogenesis in prognosis 97-107, 109-116
with S-phase in prognosis 59-71
endocrine therapy
high-dose toremifene after tamoxifen failure 223-228
resistance associated with positive EGF receptor 73-83
response association with EGFR, ER, Ki67, c-erbB-2 117-126
tamoxifen synergism with 1,25-dihydroxy-vitamin D_3 161-168
epidermal growth factor
see EGF
erbB-2
amplification and poor prognosis, vs. int-2 237-245
and EGFR in prognosis 51-58
prognostic factor in poor risk patients 287-295
vs. EGFR, ER, and Ki67 117-126
estradiol
polyamines and ornithine decarboxylase induction in MCF-7 cells 189-201
estrogen receptor
and EGF receptor regulation 29-40
and EGFR in long-term prognosis 73-83
no change on transformation of MCF-10 cells 169-177
vs. EGFR, Ki67, erbB-2 in predicting endocrine response 117-126
vs. EGFR and angiogenesis in prognosis 109-116
vs. treatment response and prognosis in stage III 259-264

fat
see dietary fat
flow cytometry
ploidy and S-phase in prognosis for medullary carcinoma 297-306
S-phase on cytokeratin-positive cells 179-187

gene amplification
of erbB-2 vs. int-2 by PCR in prognosis 237-245

HER-2/*neu* oncogene
see erbB-2
heregulin
EGF-related ligands in autocrine/juxtacrine growth 11-27
histologic grade
and c-erbB-2 in prognosis 287-295
vs. treatment response and prognosis in stage III 259-264
hormone responsiveness
induction of Zn-α_2-glycoprotein by glucocorticoids, androgens 247-258
humanized antibodies
human:mouse chimeric antibody targeting EGFR in therapy 127-138

ifosfamide
combination with doxorubicin 271-277
int-2
amplification prognostically neutral, vs. c-erbB-2 237-245

juxtacrine growth factors
EGF-related peptides 11-27

Ki67
measure of proliferation, association with positive EGFR 51-58, 59-71, 117-126

lymphocyte populations
tamoxifen aids recovery after radiotherapy 279-285

MCF-7 breast cancer cells
inhibition by tamoxifen plus 1,25-dihydroxy-vitamin D_3 161-168
polyamine requirement, and ornithine decarboxylase induction by estradiol 189-201
MCF-10 breast epithelial cells
transformation vs. EGFR, ER, PgR, and cathepsin D content 169-177
medullary carcinoma of the breast
ploidy and S-phase in prognosis 297-306
microvessel density
as a measure of angiogenesis in prognosis 97-107, 109-116
mitotic index
vs. treatment response and prognosis in stage III 259-264

monoclonal antibodies
targeting EGFR, therapeutic effectiveness 127-138

natural killer cell (NK) activity
tamoxifen inhibits recovery after radiotherapy 279-285

oncogenes
see erbB-2, int-2, ras
oral contraceptive use
and c-erbB-2 in prognosis 287-295
ornithine decarboxylase
induction by estradiol in MCF-7 cells 189-201

PCR (polymerase chain reaction)
for amplification assay of erbB-2, int-2 237-245
personality
in breast cancer risk and progression 141-160
phagocytosis
tamoxifen inhibits recovery after radiotherapy 279-285
phosphorylation
and EGF receptor signal transduction 29-40
ploidy
and prognosis in medullary carcinoma 297-306
vs. treatment response and prognosis in stage III 259-264
polyamines
estradiol stimulation; growth requirement for MCF-7 cells 189-201
prevention
effect of natural dehydroepiandrosterone levels 203-217
progesterone receptor
and c-erbB-2 in prognosis 287-295
in long-term prognosis 73-83
no change on transformation of MCF-10 cells 169-177
vs. treatment response and prognosis in stage III 259-264
prognosis
c-erbB receptor family 3-9
prognostic factors
c-erbB-2 overexpression 287-295
amplification of c-erbB-2, vs. int-2 237-245
angiogenesis and EGF receptor 97-107, 109-116
prognostic factors (cont.)
EGF receptor not significant 265-270
EGF receptor in 3009 patients 41-49
EGF receptor and S-phase 59-71
EGF receptor and erbB-2 51-58
EGF receptor, ER, PgR in long-term prognosis 73-83
for treatment response and survival in stage III 259-264
histologic grade 287-295
immunoenzymatic assay for solubilized EGFR 85-95
oral contraceptive use 287-295
p53, erbB-2, cathepsin D, nodal status with EGFR 59-71
ploidy and S-phase in medullary carcinoma 297-306
S-phase on cytokeratin-positive cells 179-187
TGFα 229-235
TNFα 229-235
see also individual factors
proliferating cell nuclear antigen (PCNA)
not a prognostic factor 287-295
promoter
regulatory elements in EGFR gene 29-40
psychosocial factors
in development and progression of breast cancer 141-160

radiotherapy
lymphocyte recovery aided by tamoxifen 279-285
ras transfection
transformation of MCF-10 cells 169-177

S-phase
and prognosis in medullary carcinoma 297-306
determination by flow cytometry on cytokeratin-positive cells 179-187
signal transduction
role of EGF receptor 29-40
stress
in risk or protection from breast cancer 141-160

T-47D breast cancer cells
induction of Zn-α_2-glycoprotein by glucocorticoids, androgens 247-258

tamoxifen
high-dose toremifene after failure 223-228
possible antioxidant benefit 307-308
stimulates recovery of lymphocytes, not phagocytosis, after radiotherapy 279-285
synergism with 1,25-dihydroxy-vitamin D_3 161-168
TGFα
and EGF receptor regulation 29-40
and poor prognosis, by immunohistochemistry 229-235
EGFR ligands in autocrine/juxtacrine growth 11-27
toremifene
high-dose, after tamoxifen failure 223-228
transforming growth factors
see TGFs
tumor necrosis factor alpha (TNFα)
and good prognosis, by immunohistochemistry 229-235
vascular count
as a measure of angiogenesis in prognosis 109-116
vascular invasion
no association with treatment response and prognosis in stage III 259-264
vitamin D_3
1,25-dihydroxy, synergism with tamoxifen 161-168

Zn-α_2-glycoprotein
induction by glucocorticoids, androgens in T-47D cells 247-258
ZR-75-1 breast cancer cells
inhibition by tamoxifen plus 1,25-dihydroxy-vitamin D_3 161-168